Texas Dermatology Research Center | Plano, TX
Status and phase
Conditions
Treatments
About
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to day 1 pre-randomization.
Treatment with any of the following medications or therapies within 5 half-lives prior to day 1 pre-randomization:
Treatment with any of the following medications or therapies within 1 week before day 1 pre-randomization:
Primary purpose
Allocation
Interventional model
Masking
100 participants in 2 patient groups
Loading...
Central trial contact
Amgen Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal